Antineoplastic Combined Chemotherapy ProtocolsInflammationTumor Necrosis Factor-alphaInflammation MediatorsCytokinesChemotherapy, AdjuvantMice, Inbred C57BLLipopolysaccharidesMacrophagesNF-kappa BInterleukin-6Interleukin-8Cells, CulturedSignal TransductionCell Line, TumorCombined Modality TherapyAntineoplastic AgentsToll-Like Receptor 4Tumor Markers, BiologicalCisplatinToll-Like Receptor 2Treatment OutcomeMice, KnockoutRNA, MessengerDoxorubicinCell LineCyclophosphamideTumor BurdenMonocytesInterleukin-1betaMice, Inbred BALB CNeoplasm StagingTime FactorsInterleukin-1Gene Expression RegulationReverse Transcriptase Polymerase Chain ReactionUp-RegulationMyeloid Differentiation Factor 88Breast NeoplasmsChemokinesSeoul virusDisease Models, AnimalDisease-Free SurvivalSurvival AnalysisNeoadjuvant TherapyToll-Like ReceptorsEpithelial CellsImmunity, InnateLungSurvival RateInterleukin-10Brain NeoplasmsNeoplasmsWilms TumorNeoplasm MetastasisDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayPrognosisAdenocarcinomaEtoposideGene ExpressionLung NeoplasmsApoptosisBlotting, WesternMicrogliaInterferon-gammaNeoplasm Recurrence, LocalNeoplasms, ExperimentalMacrophage ActivationNeutrophilsChemokine CCL2Flow CytometryTumor Suppressor Protein p53Cell ProliferationDrug Administration ScheduleEndothelial CellsOvarian NeoplasmsImmunohistochemistryGenes, Tumor SuppressorDown-RegulationMethotrexateGene Expression ProfilingCarcinoid TumorAnti-Inflammatory AgentsPaclitaxelNitric Oxide Synthase Type IIp38 Mitogen-Activated Protein KinasesIntercellular Adhesion Molecule-1Liver NeoplasmsCyclooxygenase 2Dendritic CellsHMGB1 ProteinCarboplatinMice, TransgenicToll-Like Receptor 9Macrophages, PeritonealTumor Suppressor ProteinsI-kappa B ProteinsNeuroendocrine TumorsAntigens, CD14